ARDX Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -55.52% compared to Ardelyx's net margin of -49.65%. Ardelyx's return on equity of -34.68% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Ardelyx has a consensus price target of $10.80, signalling upside risk potential of 193.48%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 46.55%. Given that Ardelyx has higher upside potential than NovaBay Pharmaceuticals, analysts believe Ardelyx is more attractive than NovaBay Pharmaceuticals.

Ardelyx has a beta of 0.593, which suggesting that the stock is 40.676% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $74.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Ardelyx's net income of -$41.1M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Ardelyx's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 2.41x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -55.52% compared to Ardelyx's net margin of --. Ardelyx's return on equity of -34.68% beat Oragenics's return on equity of --.

Ardelyx has a consensus price target of $10.80, signalling upside risk potential of 193.48%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 601.01%. Given that Oragenics has higher upside potential than Ardelyx, analysts believe Oragenics is more attractive than Ardelyx.

Ardelyx has a beta of 0.593, which suggesting that the stock is 40.676% less volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $74.1M, which are larger than Oragenics quarterly revenues of --. Ardelyx's net income of -$41.1M is lower than Oragenics's net income of -$2.2M. Notably, Ardelyx's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 2.41x versus 1.37x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics has a net margin of -55.52% compared to Ardelyx's net margin of -271.3%. Ardelyx's return on equity of -34.68% beat Spero Therapeutics's return on equity of -108.26%.

Ardelyx has a consensus price target of $10.80, signalling upside risk potential of 193.48%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 100%. Given that Ardelyx has higher upside potential than Spero Therapeutics, analysts believe Ardelyx is more attractive than Spero Therapeutics.

Ardelyx has a beta of 0.593, which suggesting that the stock is 40.676% less volatile than S&P 500. In comparison Spero Therapeutics has a beta of 1.313, suggesting its more volatile than the S&P 500 by 31.286%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $74.1M, which are larger than Spero Therapeutics quarterly revenues of $5.1M. Ardelyx's net income of -$41.1M is lower than Spero Therapeutics's net income of -$13.9M. Notably, Ardelyx's price-to-earnings ratio is -- while Spero Therapeutics's PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 2.41x versus 4.81x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -55.52% compared to Ardelyx's net margin of --. Ardelyx's return on equity of -34.68% beat Theriva Biologics's return on equity of --.

Ardelyx has a consensus price target of $10.80, signalling upside risk potential of 193.48%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1389.36%. Given that Theriva Biologics has higher upside potential than Ardelyx, analysts believe Theriva Biologics is more attractive than Ardelyx.

Ardelyx has a beta of 0.593, which suggesting that the stock is 40.676% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $74.1M, which are larger than Theriva Biologics quarterly revenues of --. Ardelyx's net income of -$41.1M is lower than Theriva Biologics's net income of -$4.3M. Notably, Ardelyx's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 2.41x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.